Structure Therapeutics reports Phase 1/2a data showing 3.3% weight loss for oral amylin agonist ACCG-2671
GPCR•Aleniglipron pipeline update
Separate longer-term study results have already been presented for oral GLP-1 candidate aleniglipron, supporting durable weight loss with improved tolerability.
Two registrational Phase 3 trials for aleniglipron are enrolling, with topline results expected in 2H 2028.
Phase 1/2a data for ACCG-2671
Structure Therapeutics reported positive early-stage results for ACCG-2671, an oral amylin-based candidate for chronic weight management.
Findings have already been presented from a single-dose study, showing signs of weight reduction with a tolerable safety profile.
A longer multiple-dose trial in people with obesity is underway, with results scheduled for 1H 2027.
